GRL-0617

GRL-0617 is a drug which is one of the first compounds discovered that acts as a selective small-molecule inhibitor of the protease enzyme papain-like protease (PLpro) found in some human pathogenic viruses, including the coronavirus SARS-CoV-2. It has been shown to inhibit viral replication in silico ^[1] and in vitro.^[2][3][4][5]

GRL-0617

Identifiers
IUPAC name 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
CAS Number	1093070-16-6 Y
PubChem CID	24941262
IUPHAR/BPS	11078
DrugBank	DB08656
ChemSpider	24617535
UNII	SQH4947NDN
ChEBI	CHEBI:167176
ChEMBL	ChEMBL549695
CompTox Dashboard (EPA)	DTXSID10660795
Chemical and physical data
Formula	C20H20N2O
Molar mass	304.393 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
InChI InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1 Key:UVERBUNNCOKGNZ-CQSZACIVSA-N

See also

• 3CLpro-1
• Ebselen
• GC376